Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Downgraded by Zacks Research to Hold

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Thursday,Zacks.com reports.

Other research analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Canaccord Genuity Group raised their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a report on Wednesday. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Wells Fargo & Company boosted their price objective on Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Finally, Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of “Moderate Buy” and an average price target of $87.38.

Kiniksa Pharmaceuticals International Stock Down 4.9%

Shares of Kiniksa Pharmaceuticals International stock opened at $74.34 on Thursday. The stock has a market capitalization of $5.72 billion, a P/E ratio of 76.64 and a beta of 0.07. The company has a 50-day simple moving average of $59.04 and a 200 day simple moving average of $51.13. Kiniksa Pharmaceuticals International has a 12-month low of $29.90 and a 12-month high of $82.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, meeting analysts’ consensus estimates of $0.30. The firm had revenue of $243.60 million for the quarter, compared to analyst estimates of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. On average, equities analysts anticipate that Kiniksa Pharmaceuticals International will post 1.38 earnings per share for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In related news, Director G Bradley Cole sold 3,673 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $81.43, for a total value of $299,092.39. Following the completion of the transaction, the director owned 11,672 shares in the company, valued at $950,450.96. The trade was a 23.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 51.98% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Amundi bought a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter worth $348,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Kiniksa Pharmaceuticals International by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company’s stock valued at $507,000 after acquiring an additional 1,002 shares during the last quarter. Millennium Management LLC increased its position in Kiniksa Pharmaceuticals International by 8.7% in the first quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after purchasing an additional 67,452 shares during the period. Creative Planning acquired a new stake in Kiniksa Pharmaceuticals International in the second quarter worth about $358,000. Finally, Quantbot Technologies LP bought a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth about $43,000. 53.95% of the stock is currently owned by institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.